A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study

Archives of Gynecology and Obstetrics

Volumn 281, Issue 5, 2010, Pages 845-850

  Han, Chih Ping ^a,b   Lee, Ming Yung ^a   Kok, Lai Fong ^c   Wu, Tina S ^d   Cheng, Ya Wen ^b   Wang, Po Hui ^a   Yue, Chia Herng ^e   Tyan, Yeu Sheng ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN ANTIBODY; TUMOR MARKER; VIMENTIN;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 77950604655     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1151-8     Document Type: Article

References (25)

1. Lurain JR, Bidus MA, Elkas JC (2007) Uterine cancer, cervical and vaginal cancer. In: Berek RS (ed) Novak's gynecology, 14th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1343-1402
2. Schorge JO, Knowles LM, Lea JS (2004) Adenocarcinoma of the cervix. Curr Treat Options Oncol 5:119-127
3. INK4a adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet. 20 January 2009 (Epub ahead of print)
4. Remmele W, Schicketanz KH (1993) Immunohistochemical determination of estrogen, progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189:862-866
5. Walker RA (2006) Quantification of immunohistochemistry: Issues concerning methods, utility and semiquantitative assessment I. Histopathology 49:406-410
6. Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry: Issues concerning methods, utility and semiquantitative assessment II. Histopathology 49:411-424
7. Zweig MH, Campbell G (1993) Receiver-Operating Characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577
8. Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8:283-298
9. Kamoi S, AlJuboury MI, Akin MR, Silverberg SG (2002) Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: Another viewpoint. Int J Gynecol Pathol 21:217-223
10. Khoury T, Tan D, Wang J, Intengan M, Yang J, Alrawi S, Yan P, Byrd JC (2006) Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma. BMC Clin Pathol 6:1
11. Han CP, Lee MY, Tzeng SL, Yao CC, Wang PH, Cheng YW, Chen SL, Wu TS, Tyan YS, Kok LF (2008) Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res 27:25
12. INK4a immunohistochemistry based on independent nucleic staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue micro-array study. Mod Path 22:797-806
13. INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 7:25
14. Liao CL, Lee MY, Tyan YS, Kok LF, Wu TS, Koo CL, Wang PH, Chao KC, Han CP (2009) Progesterone receptor does not improve the performance and test effectiveness of the conventional three-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue micro-array extension study. J Transl Med 7:37
15. Bodner G, Schocke MF, Rachbauer F, Seppi K, Peer S, Fierlinger A, Sununu T, Jaschke WR (2002) Differentiation of malignant and benign musculoskelet al tumors: Combined color and power Doppler US and spectral wave analysis. Radiology 223:410-416
16. McCluggage WG, Sumathi VP, McBride HA, Patterson A (2002) A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 21:11-15
17. Wehling M (2008) Translational medicine: Science or wishful thinking? J Transl Med 6:31
18. Dabbs DJ, Sturtz K, Zaino RJ (1996) Distinguishing endometrial from endocervical adenocarcinoma. Hum Pathol 27:172-177
19. Castrillon DH, Lee KR, Nucci MR (2002) Distinction between endometrial and endocervical adenocarcinoma: An immunohistochemical study. Int J Gynecol Pathol 21:4-10
20. Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M et al (2003) Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 442:271-277
21. Miller RT (2002) Endocervical vs. endometrial adenocarcinoma. THE FOCUS-Immunohistochemistry Jan: 1-2
22. Miller RT (2003) Endocervical vs. endometrial adenocarcinoma: Update on useful immunohistochemical markers. THE FOCUS-Immunohistochemistry. Apr: 1-2
23. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA (2006) Immunophenotypic diversity of endometrial adenocarcinomas: Implications for differential diagnosis. Mod Pathol 19(8):1091-1100 (Epub 28 April 2006)
24. McCluggage WG, Jenkins D (2003) p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 22:231-235
25. Mittal K, Soslow R, McCluggage WG (2008) Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 132:402-423